SCHEMBL172839

SCHEMBL172839

CCNCCCCCC(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 1/20 0.57
GPR84 Q9NQS5 7/20 0.56
PPARG P37231 7/20 0.56
PPARD Q03181 7/20 0.56
PPARA Q07869 7/20 0.56
HDAC11 Q96DB2 5/20 0.56
TSHR P16473 5/20 0.56
PTPN1 P18031 3/20 0.56
ALDH1A1 P00352 2/20 0.56
TLR2 O60603 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
FABP4 P15090 2/20 0.56
SLC22A6 Q4U2R8 1/20 0.56
SLC22A8 Q8TCC7 1/20 0.56
MEN1 O00255 1/20 0.56
ESR1 P03372 1/20 0.56
ALOX15 P16050 1/20 0.56
PDE4A P27815 1/20 0.56
KMT2A Q03164 1/20 0.56
PDE3A Q14432 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8388402 1.00 ADRA1A (0.57) ADRA1AGPR84PPARGPPARDPPARA
SCHEMBL11516867 1.00 ADRA1A (0.57) ADRA1AGPR84PPARGPPARDPPARA
SCHEMBL31536450 1.00 ADRA1A (0.57) ADRA1AGPR84PPARGPPARDPPARA
SCHEMBL28622058 1.00 ADRA1A (0.57) ADRA1AGPR84PPARGPPARDPPARA
Azelaic Acid SCHEMBL11513754 1.00 ADRA1A (0.57) ADRA1AGPR84PPARGPPARDPPARA
SCHEMBL21634549 1.00 ADRA1A (0.57) ADRA1AGPR84PPARGPPARDPPARA
SCHEMBL9259807 1.00 ADRA1A (0.57) ADRA1AGPR84PPARGPPARDPPARA
SCHEMBL2209285 1.00 ADRA1A (0.57) ADRA1AGPR84PPARGPPARDPPARA
SCHEMBL11540844 1.00 ADRA1A (0.57) ADRA1AGPR84PPARGPPARDPPARA
Hydrochloric Acid SCHEMBL16059309 0.98 ADRA1A (0.55) ADRA1AGPR84PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4257154-A1 BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF Medilink Therapeutics (Suzhou) Co., Ltd. (CN) 2023-10-11 EP disclosed
EP-3564252-B1 MODIFIED NUCLEOTIDE LINKERS ILLUMINA CAMBRIDGE LTD (GB) 2021-03-17 EP disclosed
EP-3104846-B1 MAO INHIBITORS AND THEIR CONJUGATES AS THERAPEUTICS FOR THE TREATMENT OF BRAIN CANCER UNIV SOUTHERN CALIFORNIA (US) 2020-10-14 EP disclosed
WO-2020020905-A1 NEAR-INFRARED (NIR) TRICARBOCYANINE N-TRIAZOLE CHROMOPHORES THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) 2020-01-30 WO disclosed
WO-2018100089-A1 MEANS AND METHODS FOR VISUALIZATION OF TISSUE STRUCTURES GRETZ NORBERT (DE) 2018-06-07 WO disclosed
US-20150301451-A1 PATTERN FORMING METHOD, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM, METHOD FOR MANUFACTURING ELECTRONIC DEVICE, AND ELECTRONIC DEVICE FUJIFILM CORPORATION (JP) 2015-10-22 US disclosed
EP-1979331-B1 TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP MITSUBISHI TANABE PHARMA CORP (JP) 2012-03-07 EP disclosed
EP-2233495-A1 GLYCOSYLATED GLYCOPEPTIDE ANTIBIOTIC DERIVATIVE Shionogi & Co., Ltd. (JP) 2010-09-29 EP disclosed
US-20090280106-A1 Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use BAYER PHARMACEUTICALS CORPORATION (US) 2009-11-12 US disclosed
EP-1818340-A1 GLYCOPEPTIDE ANTIBIOTIC MONOMER DERIVATIVES National University Corporation Nagoya University (JP) 2007-08-15 EP disclosed
WO-2007088996-A1 TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-08-09 WO disclosed
US-4217238-A BASIC SALT, SCRUBBING EXXON RESEARCH & ENGINEERING CO. (US) 1980-08-12 US disclosed
US-4217237-A Process for removing carbon dioxide containing acidic gases from gaseous mixtures using a basic salt activated with a hindered amine EXXON RESEARCH & ENGINEERING CO. (US) 1980-08-12 US disclosed
US-4112050-A Process for removing carbon dioxide containing acidic gases from gaseous mixtures using a basic salt activated with a hindered amine EXXON RESEARCH & ENGINEERING CO. (US) 1978-09-05 US disclosed
US-4094957-A CARBON DIOXIDE EXXON RESEARCH & ENGINEERING CO. (US) 1978-06-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090280106-A1 Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use ADCYAP1R1, VIPR2, ADCY2 ADRA1A 536/4885GPR84 170/4885PPARG 1340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.